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Background:Routine administration of quadrivalentmeningococcal conjugate vaccine to adolescents and
certain high risk groups is recommended in the United States and Canada. We compared the immuno-
genicity and safety of an investigational quadrivalent meningococcal vaccine conjugated to CRM-197
(MenACWY-CRM) with a licensed quadrivalent vaccine conjugated to diphtheria toxoid (MCV4) in chil-
dren aged 2–10 years.
Methods: Eligible 2–5-year-olds were randomized 1:2:2 to receive either 2 doses of MenACWY-CRM,
or 1 dose of MenACWY-CRM or MCV4; 6–10-year-olds were randomized 1:1 to receive a single dose
of MenACWY-CRM or MCV4. The primary immunogenicity assessment was seroresponse separately for
the two age cohorts 28 days following a single dose of MenACWY-CRM or MCV4. Noninferiority and
superiority criteria were predeﬁned. Solicited injection-site and systemic reactions were collected for
the 7 days postvaccination.
Results:Atotal of 2907childrenwere randomized to receive studyvaccine.MenACWY-CRMmet statistical
superiority criteria vs. MCV4 for groups W and Y and was noninferior for group C in both age strata. For
group A, noninferiority criteria were not met; the group A seroresponse rates for MenACWY-CRM and
MCV4, respectively were 72% (95% conﬁdence interval 68–75%) and 77% (73–80%) in 2–5-year-olds and
77% (73–80%) and 83% (79–86%) in 6–10-year-olds. When the two age strata were combined (2–10-year-
old children), MenACWY-CRM was noninferior to MCV4 for all four groups, and statistically superior for
groups C, W, and Y. Safety parameters were similar across age cohorts and vaccines groups.
Conclusions: MenACWY-CRM and MCV4 were immunogenic and well tolerated in children aged 2–10
years. Seroresponse to MenACWY-CRM was statistically noninferior to MCV4 for all groups, and statisti-
C, W,
rials.cally superior for groups
Trial registration: Clinicalt
. Introduction
Neisseriameningitidis is a gram-negative diplococcus that causes
evere invasive disease including septicemia and meningitis [1].
ost invasive disease is the result of infection with one of ﬁve
roups (A, B, C, Y, W-135) as characterized by their capsular
olysaccharide [2]. Epidemic groupAdiseaseoccurs in sub-Saharan
∗ Corresponding author. Tel.: +1 902 470 8141; fax: +1 902 470 7232.
E-mail address: scott.halperin@dal.ca (S.A. Halperin).
1 For the V59P20 investigators (see Appendix A).
264-410X © 2010 Elsevier Ltd. 
oi:10.1016/j.vaccine.2010.09.092
Open access under CC BY-NC-ND license. and Y.
gov identiﬁer: NCT00616421.
© 2010 Elsevier Ltd. 
Africa, the Middle East and in some areas of Asia [3–5]. Endemic
group B and C disease predominates in Europe and North America;
an increase in group Y disease has been reported over the last 20
years in the United States [6]. Outbreaks of W-135 disease have
been reported in the Middle East and Africa [4,7]. Meningococcal
disease is seen in all age groups including children 2–10 years of
age; in the US, groups A, C, Y and W-135 account for approximately
Open access under CC BY-NC-ND license. 60% of meningococcal disease [8].
Using similar conjugation technology that led to the develop-
ment of effective vaccines against Haemophilus inﬂuenzae type b
and pneumococcal diseases in infants and young children [9,10],
group C meningococcal conjugate vaccines (MenC) were devel-
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ped that led to dramatic decreases in invasive disease caused by
. meningitidis group C in European countries and Australia where
niversal immunization programs were implemented [11–14]. By
hemically conjugatingcapsularpolysaccharide toaprotein carrier,
he polysaccharide antigen is converted from a T-cell independent
ntigen to a T-cell dependent antigen with the resultant induction
n immune memory in all ages after immunization and improved
mmunogenicity in infants [15–17].
Aquadrivalentmeningococcal conjugatevaccinewasdeveloped
n an attempt to improve upon the quadrivalent meningococ-
al polysaccharide vaccine that has been available for decades.
enactra® (MCV4; Sanoﬁ Pasteur, Swiftwater, PA) was licensed
or use in the United States January 17, 2005, for individuals 11–55
ears of age and October 19, 2007, for children 2–10 years of
ge, and is recommended for universal use as a preadolescent
ose [18] and for children 2–10 years of age with increased risk
f meninogococcal infection [19,20]. Menveo® (MenACWY-CRM;
ovartis Vaccines and Diagnostics, Cambridge, MA), a quadriva-
ent meningococcal conjugate vaccine, was recently licensed in the
nited States February 19, 2010, for individuals 11–55 years of
ge and in Canada on May 21, 2010 for individuals 11 years and
lder; further studies were undertaken to support its use in infants
21–23] and younger children [24]. The purpose of this study was
o compare the safety and immunogenicity of MenACWY-CRM to
he licensed MCV4 vaccine in children 2–10 years of age.
. Methods
.1. Vaccines
The investigational quadrivalent meningococcal conjugate
accine (MenACWY-CRM; Menveo®, Novartis Vaccines and Diag-
ostics, Cambridge, MA) contained (per 0.5mL dose) 10g of
eningococcal group A capsular polysaccharide and 5g each
f group C, W-135 and Y capsular polysaccharides conjugated to
RM197 (Table 1). The vaccine was prepared by mixing, just before
njection, theMenCWY liquid suspension and the lyophilizedMenA
owder. The comparison vaccine was the licensed quadrivalent
eningococcal vaccine conjugated to diphtheria toxoid (MCV4,
enactra®, Sanoﬁ Pasteur, Swiftwater, PA) containing (per 0.5mL
ose) 4g each of meningococcal groups A, C, Y and W135 cap-
ular polysaccharide conjugated to diphtheria toxoid. MCV4 was
upplied in single-dose vials and did not require mixing.
.2. Study populationHealthy children 2–10 years of age who were up to date
ith their routine childhood immunizations, had never previ-
usly received any meningococcal vaccine and had no history
able 1
tudy vaccine composition.
Constituent Quantity per 0.5mL dose
MCV4 MenACWY-CRM
Group A polysaccharide 4g 10g
Group C polysaccharide 4g 5g
Group Y polysaccharide 4g 5g
Group W135 polysaccharide 4g 5g
Protein carrier 48ga 47gb
Sodium chloride 4.4mg 4.5mg
Sodium phosphate 0.6mg 10mM
Postassium dihydrogen phosphate – 5mM
Sucrose – 12.5mg
ach polysaccharide in each vaccine was conjugated to a protein carrier.
a Diphtheria toxoid total protein.
b CRM197 toxoid total protein.28 (2010) 7865–7872
of meningococcal infection were recruited into the study at 27
American and 16 Canadian sites. Children were excluded from
participation if they had known or suspected HIV infection, were
immunocompromised or receiving immunosuppressive therapy,
had received immunoglobulin, blood or blood products or any
experimental vaccineswithin 90 days, had a history of neurological
disease, developmental delay, seizures, bleeding diathesis, had any
serious acute or chronic medical condition, or had a hypersensitiv-
ity to any component of the vaccine.
2.3. Study design and procedures
The study was a phase 3, multicenter, partially observer-blind
(described below), randomized, controlled trial. Written informed
consent was obtained from the parents or guardian prior to any
study procedure; the study protocol was approved by the Research
Ethics Board or Institutional Review Board of each participating
center. Study visits took place from 13 March, 2008 to 14 October,
2009. Participants 2–5 years of age were randomly allocated in a
1:2:2 ratio to receive either two doses ofMenACWY-CRM, one dose
of MenACWY-CRM or one dose of MCV4. Participants 6–10 years of
age were randomly allocated in a 1:1 ratio to receive a single dose
of MenACWY-CRM or MCV4. Randomization was achieved within
each age stratumusing a center-stratiﬁed, computer-generated list
provided by the Biostatistics and Clinical Data Management group
ofNovartisVaccines andDiagnostics. Participants (2–5years of age)
allocated to the two-dose MenACWY-CRM group received the vac-
cines in an open-label fashion. Participants either 2–5 or 6–10 years
of age allocated to receive a single dose ofMenACWY-CRMorMCV4
received their vaccine in an observer-blinded manner.
MenACWY-CRM or MCV4 was given by 0.5mL intramuscu-
lar injection in the left deltoid area. Participants allocated to the
two-dose MenACWY-CRM received the second dose after a 60-day
interval. All participants were monitored by study staff for 30min
after each injection for immediate reactions. Parents recorded in
a standardized symptom diary daily the following solicited symp-
toms for 7 days after each vaccination: temperatures (axillary route
in 2–5-year-olds; oral route in 6–10-year-olds), injection-site reac-
tions (pain, erythema, induration) and systemic reactions (change
in eating habits, sleepiness, irritability, vomiting, diarrhea, arthral-
gia, headache, rash and fever in 2–5-year-olds and chills, nausea,
malaise, myalgia, arthralgia, headache, rash and fever in 6–10-
year-olds). Solicited adverse events were either measured (fever,
erythema, swelling) or categorized by the parents as mild (no lim-
itation of normal daily activities), moderate (some limitation of
normal daily activities) or severe (unable to perform normal daily
activities). Medically signiﬁcant events, such as hospitalizations,
and other serious adverse events were collected for six months fol-
lowing vaccination. All unsolicited adverse events were collected
and tabulated by preferred term and body system.
Blood was collected by venipuncture immediately before and
approximately 28 days after vaccination (after the second dose
in the two-dose group). Functional antibody to each of the four
meningococcal groupswasmeasured by a serumbactericidal assay
using human complement (hSBA) and reported as reciprocal dilu-
tion (RD) [21,25,26]. All antibody measurements were performed
by Novartis Vaccines and Diagnostics (Marburg, Germany).
2.4. Data analysis and statistical considerations
Theprimary objective of the studywas to compare the immuno-
genicity of a single dose of MenACWY-CRM with a single dose of
MCV4 in children 2–5 years of age and children 6–10 years of age.
Immunogenicity was characterized as the percentage of subjects
achieving a seroresponse against each of the four groups (A, C,
W and Y). Seroresponse was deﬁned as a four fold or greater rise
S.A. Halperin et al. / Vaccine 28 (2010) 7865–7872 7867
Table 2
Characteristics of the study population.
Characteristics 2–5 years 6–10 years Total (2–10 years)
MCV4 1 dose
(n=696)
MenACWY-
CRM 1 dose
(n=696)
MenACWY-
CRM 2 doses
(n=359)
MCV4 1 dose
(n=574)
MenACWY-
CRM 1 dose
(n=582)
MCV4 1 dose
(n=1270)
MenACWY-
CRM 1 dose
(n=1278)
Mean age, years (SD) 3.5 (1.1) 3.5 (1.1) 3.5 (1.1) 8.1 (1.4) 7.9 (1.4) 5.6 (2.6) 5.5 (2.5)
Female, n (%) 331 (48) 342 (49) 171 (48) 249 (43) 280 (48) 580 (46) 622 (49)
Race, n (%)
Asian 25 (4) 36 (5) 19 (5) 34 (6) 31 (5) 59 (5) 67 (5)
Black 94 (14) 89 (13) 44 (12) 81 (14) 79 (14) 175 (14) 168 (13)
Caucasian 425 (61) 419 (60) 220 (61) 378 (66) 387 (66) 803 (63) 806 (63)
Hispanic 98 (14) 107 (15) 55 (15) 39 (7) 40 (7) 137 (11) 147 (12)
Other 54 (8) 45 (6) 21 (6) 42 (7) 45 (8) 96 (8) 90 (7)
Mean weight, kg (SD) 17.35 (3.88) 17.37 (4.02) 17.40 (4.05) 31.19 (9.78) 31.90 (10.06) 23.62 (9.95) 23.99 (10.36)
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D, standard deviation.
n group-speciﬁc antibody; in participants with a prevaccination
ntibody titer <4, seroresponse was deﬁned as an hSBA of ≥8. Sec-
ndary objectives included evaluation of the geometric mean hSBA
ntibody titers (hSBA GMTs) and the proportion of participants
chieving hSBA titers ≥8 (seroprotection). Additional secondary
bjectives were to assess the safety and tolerability of all the vac-
ines administered and to assess the immunogenicity (as deﬁned
y all of the above immunogenicity parameters) of two doses of
enACWY-CRM in children 2–5 years of age.
All subjects who received at least one dose of vaccine were
ncluded in the safety analysis. Adverse events were tabulated and
he maximum severity reported for each time period was used.
he proportion of participants having an adverse event by vaccine
roup was calculated with 95% conﬁdence intervals (CIs).
All subjects who received all the protocol-speciﬁed doses of
accine correctly, provided evaluable serum samples at the rele-
ant time points, and had no major protocol violation as deﬁned
rior to database lock and unblinding were part of the per-protocol
mmunogenicity analysis population. A major protocol violation
as deﬁned as one thatwas considered to have a signiﬁcant impact
n the immunogenicity results of the subject. The percentage of
articipants with a seroresponse or who were seroprotected, along
ith the associated Clopper–Pearson 95% conﬁdence intervals,
ere computed. Immunogenicity of MenACWY-CRM was consid-
red noninferior to MCV4 for any of the 4 groups if the lower limit
f the two-sided 95% conﬁdence interval around the difference of
he percentage of participants with a seroresponse (or hSBA ≥8)
or that group (MenACWY-CRM minus MCV4) was greater than
10%. A MenACWY-CRM group was considered to have a statis-
ically superior immune response compared to MCV4 if the lower
imit of the two-sided 95% conﬁdence interval around the differ-
nce in percentage of participantswas greater than 0 (i.e., the CI did
ot include 0). Geometric mean titers (GMTs) and two-sided 95%
Is were calculated for each vaccine group and for each group pre-
nd postvaccination by exponentiating (base 10) the least-squares
eans of the logarithmically transformed (base 10) titers and their
5% CIs obtained from a two-way Analysis of Variance (ANOVA)
ith factors for vaccine group and center. Titers below the detec-
ion limit were set to half that limit for the purpose of analysis. As
n additional secondary objective analysis, the immunogenicity of
he combined group of children aged 2–10 years was analyzed.
A sample size of 680 per group in the 2–5-year-olds and 560
er group for the 6–10-year-olds was estimated to provide 95–99%
ower to demonstrate noninferiority for each of the four groups,
8% power within each age group to demonstrate noninferiority
or all four groups and 77% power to show noninferiority of all four
roups across both age strata (2–10 years of age). Inclusion of 325
articipants who received the two-dose MenACWY-CRM regimen131.45 (10.74) 131.03 (11.01) 115.54 (17.78) 115.31 (17.83)
was calculated to provide 84–94% power to demonstrate superior-
ity of the two-dose regimen in children 2–5 years of age at alpha of
0.05.
3. Results
3.1. Demographics and participant disposition
A total of 2907 children between 2 and 10 years of age were
enrolled in the study. There were 1751 children 2–5 years of age
randomly allocated 1:2:2 to receive two doses of MenACWY-CRM
(n=359), one dose of MCV4 (n=696), or one dose of MenACWY-
CRM (n=696). There were 1156 children 6–10 years of age
randomly allocated 1:1 to receive MCV4 (n=574) or MenACWY-
CRM (n=582). The male/female distribution, race, and weight and
height were similar within each age stratum (Table 2).
In total, 2802 (96.4%) participants completed the protocol
(Fig. 1). Therewere105prematurewithdrawals (26 in the two-dose
MenACWY-CRMgroup, 27 in the single-doseMenACWY-CRM2–5-
year-old group, 24 in the single-dose MCV4 2–5-year-old group, 11
in the single-dose MenACWY-CRM 6–10-year-old group and 17 in
the single-dose MCV4 6–10-year-old group). For the entire par-
ticipant population, 68 participants withdrew as a result of loss
to follow-up, 28 participants withdrew consent, 4 subjects were
deemed to be ineligible according to the inclusion and exclusion
criteria, three participants were withdrawn because of a proto-
col violation, one for an administrative reason, and one withdrew
after consent was obtained but prior to vaccination. There were no
withdrawals related to an adverse event. An additional 9 enrolled
subjects did not receive a vaccine due to withdrawal of con-
sent (n=7), inappropriate enrollment (n=1) or inability to obtain
baseline serology (n=1); all subjects who received a dose of the
vaccine were included in the safety analysis to the extent that
data were available. A total of 279 participants (including the 9
participants who were unvaccinated) were excluded from the per-
protocol immunogenicity analysis. The main reason for exclusion
was a missing prevaccination (n=60) or postvaccination (n=130)
specimen. Ten subjects who received the wrong vaccine product
were excluded from the immunogenicity analysis but included “as
treated” in the safety analysis.
3.2. Adverse eventsLocal or systemic adverse events after vaccination with a sin-
gle dose of MenACWY-CRM or MCV4 were common, reported
by 60% and 51%, respectively (Tables 3a and 3b). Erythema and
pain were the most commonly reported injection-site reactions
in both the 2–5 and 6–10 years age groups; in the 2–5 years age
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roup, there were no differences between the vaccines. In the 6–10
ears age group, signiﬁcantly fewer participants reported pain after
enACWY-CRM than MCV4 (39% vs. 45%; p=0.039). In contrast,
ewer MCV4 than MenACWY-CRM recipients reported injection-
ite erythema (22% vs. 28%; p=0.017). Severe pain or erythema
100mm in the 6–10 years age group was unusual postvaccina-
ion with non signiﬁcant trends toward higher rates of erythema
ost-MenACWY-CRM and pain post-MCV4.
Rates of systemic adverse events were similar in recipients of
enACWY-CRM and MCV4 (Tables 3a and 3b). In the 2–5-year-
ld children, irritability was the most common reported systemic
dverse event (21% and 22%, respectively), followed by sleepi-
ess (16% and 18%, respectively); fever ≥38 ◦C was only reported
y 2% of participants. Headache was the most common systemic
able 3a
ercent (95% conﬁdence interval) of 2–5-year-olds with solicited reactions by vaccine gro
Single dose
MCV4 (n=684) % (95% CI) MenACWY-CRM (n=693)
Injection-site reactions
Erythema 25 (22–28) 27 (24–30)
Induration 18 (16–22) 18 (15–21)
Pain 35 (32–39) 33 (29–36)
Systemic reactions
Change in eating 10 (8–13) 9 (7–12)
Sleepiness 18 (16–22) 16 (13–19)
Irritability 22 (19–26) 21 (18–24)
Vomiting 3 (2–5) 3 (2–5)
Diarrhea 8 (6–10) 7 (5–9)
Arthralgia 4 (2–5) 3 (2–5)
Headache 6 (4–8) 5 (3–7)
Rash 5 (3–7) 4 (3–6)
Fever ≥38 ◦C 2 (1–4) 2 (1–4)
o statistically signiﬁcant differences were observed for the primary comparison betwee
iary card data were available.ant ﬂow chart.
adverse event in the 6–10-year-old children, reported by 18% of
MenACWY-CRM recipients and 13% of MCV4 recipients (p=0.049).
There were no differences between the groups for any other sys-
temic adverse events. Most adverse events in the 2–5 and 6–10
years age groups were reported as mild; rates of severe adverse
events never exceeded 2% for either vaccine.
There were also no differences between the groups in the rates
of non solicited adverse events between the MenACWY-CRM (26%)
and theMCV4 (24%) groups (datanot shown).Most of these adverse
events (10% and 11%, respectively) were related to minor intercur-
rent infectious diseases such as upper respiratory tract infection.
An adverse event was reported by 72% of two-dose recipients,
likely reﬂecting receipt of an additional dose and thus two seven-
day observation periods. In the two-dose group, adverse events
up.
Two doses MenACWY-CRM
% (95% CI) Dose 1 (n=351) % (95% CI) Dose 2 (n=334) % (95% CI)
32 (27–37) 22 (18–27)
19 (15–23) 13 (9–17)
32 (27–37) 28 (23–33)
12 (9–16) 7 (5–10)
17 (13–21) 12 (8–16)
22 (18–27) 16 (13–21)
3 (2–6) 2 (1–4)
6 (4–9) 5 (3–8)
4 (2–7) 1 (0–3)
5 (3–8) 4 (2–7)
6 (4–9) 3 (1–5)
2 (1–4) 1 (0–2)
n the single-dose groups. Percentages are based on numbers of children for whom
S.A. Halperin et al. / Vaccine
Table 3b
Percent (95% conﬁdence interval) of 6–10-year-olds with solicited reactions by vac-
cine group.
MCV4 (n=571) %
(95% CI)
MenACWY-CRM
(n=582) % (95% CI)
Injection-site reactions
Erythema 22 (19–26) 28 (25–32)a
Induration 13 (10–16) 17 (14–20)
Pain 45 (41–49)a 39 (35–43)
Systemic reactions
Chills 5 (3–7) 5 (4–7)
Nausea 6 (5–9) 8 (6–11)
Malaise 11 (8–14) 14 (11–17)
Myalgia 10 (8–13) 10 (8–13)
Arthralgia 4 (3–6) 6 (5–9)
Headache 13 (11–17) 18 (15–21)a
Rash 3 (2–5) 5 (3–7)
Fever ≥38 ◦C 2 (1–3) 2 (1–4)
Percentages are based on numbers of children for whom diary card data were avail-
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a p<0.05 vs. comparator; no other statistically signiﬁcant differences were
bserved.
ere reported less frequently after the seconddose (47%) compared
o the ﬁrst dose (63%). Rates of injection-site reactions after the sec-
nddose (28%) in the two-doseMenACWY-CRMgroupwere similar
o the rates after the ﬁrst dose (32%) in the two-dose MenACWY-
RMgroup and the single-doseMenACWY-CRMgroup (33%). There
ere no differences in severe injection-site reactions after the ﬁrst
r second dose. Irritability was also the most common systemic
dverse event after the seconddose ofMenACWY-CRM. Therewere
o differences in rates of any systemic adverse events after the ﬁrst
r second dose.
Serious adverse events were reported by a total of 17 par-
icipants during the trial and were all related to hospitalization;
one were assessed as vaccine-related by the investigators. There
ere two participants that reported a serious adverse event in
he MenACWY-CRM two-dose group (a parvovirus infection and
ntestinal obstruction inoneparticipant andpneumonia in a second
articipant), eight participants with serious adverse events in the
enACWY-CRM one-dose group (one multiple traumatic injuries,
wo pneumonias, one bronchial hyper-reactivity, one dehydration,
ne peritonsillar abscess and a shigella and staphylococcal infec-
ion) and 7 participants with serious adverse events in the MCV4
roup (one each of pneumonia, oral cyst, excoriation, septic arthri-
is, inguinal hernia, psychiatric symptom and viral infection). Most
f these events occurred more than 6 weeks after vaccination.
.3. ImmunogenicityIn the 2–5-year-old children, seroresponsewas higher for recip-
ents of MenACWY-CRM than MCV4 for group W-135 (72% vs. 58%)
ndgroupY (66%vs. 45%) and similar for groupC (60%vs. 56%); non-
able 4
eroresponse after one dose of MCV4 or MenACWY-CRM or two doses of MenACWY-CRM
Group Proportion (95% conﬁdence interval) with seroresponsea
2–5 years 6–10 ye
MCV4 1-dose
(n=600–615)
MenACWY-CRM
1-dose
(n=593–607)
MenACWY-CRM
2-doses
(n=286–293)
MCV4 1
(n=533
A 77 (73–80) 72 (68–75) 91 (87–94) 83 (79–
C 56 (52–60) 60 (56–64) 98 (95–99) 57 (53–
Y 45 (41–49) 66 (62–70) 95 (91–97) 39 (35–
W-135 58 (54–62) 72 (68–75) 89 (85–92) 44 (40–
a Seroresponse was deﬁned as a ≥4-fold rise in group-speciﬁc hSBA antibody; in partici
iter ≥8.28 (2010) 7865–7872 7869
inferiority criteria were met for these three groups and statistical
superiority of MenACWY-CRM was demonstrated for groups W-
135 and Y (Table 4). Group A response after MenACWY-CRM (72%)
did not achieve the noninferiority criterion compared to MCV4
(77%). In 6–10-year-old children, noninferiority criteria and sta-
tistical superiority of MenACWY-CRM compared to MCV4 was also
demonstrated for group W-135 (57% vs. 44%) and group Y (58% vs.
39%); noninferiority criteria were met for group C (63% vs. 57%)
but not for group A (77% vs. 83%). For the combined 2–10 year
age cohort, noninferiority criteria were demonstrated for all four
groups and statistical superiority was demonstrated for groups C,
W-135 and Y.
Prevaccination hSBA levels against all 4 groups were similar
amongst the vaccine groups (Table 5). A signiﬁcant rise in hSBA
titers was demonstrated against all four groups in children 2–5
and 6–10 years of age. Signiﬁcantly higher postvaccination hSBA
titers were found against group C, W-135 and Y in recipients of
MenACWY-CRM thanMCV4; hSBA titers against groupAwere sim-
ilar after either vaccine. Seroprotection rates, as deﬁned as hSBA
titers ≥8, were similar prevaccination. Postvaccination, seropro-
tection rates were higher for groups W-135 and Y, lower for group
A and similar for group C in both 2–5 and 6–10-year-old children
(Fig. 2).
Baseline hSBA GMTs (Table 5) and seroprotection levels were
similar for all groups before vaccination in the single- or two-dose
MenACWY-CRM 2–5-year-old groups. Postvaccination, serore-
sponse, seroprotection and hSBA GMT were all signiﬁcantly higher
(p<0.001) in recipients of two doses of MenACWY-CRM than in
recipients of a single dose (Tables 4 and 5 and Fig. 2).
4. Discussion
The purpose of this study was to assess the safety and immuno-
genicity of a quadrivalent vaccine, MenACWY-CRM, currently
licensed for use from 11 to 55 years of age, in children 2–10
years of age in comparison with a quadrivalent vaccine (MCV4)
already licensed in this younger age group. The results of the
study demonstrate that MenACWY-CRM was well tolerated and
immunogenic in these young children andwith a similar safetypro-
ﬁle and favorable immunogenicity proﬁle compared to the licensed
MCV4 product. The data from this study, along with the data that
supported the licensure of the vaccine in adolescents and adults,
previously published data using two or three doses in the ﬁrst
year of life [21,22] and a single-dose schedule at 12 or 18 months
of age [23], now demonstrate the safety and immunogenicity of
MenACWY-CRM across the age spectrum from infancy to 55 yearsAs a result of the relatively low incidence of meninogococcal
disease, studies demonstrating the efﬁcacy of new meningococcal
vaccines are impractical. Instead, licensureofnewproducts is based
on demonstrating noninferiority in the immune response to the
in children 2–10 years of age (per protocol population).
ars Total (2–10 years)
-dose
–541)
MenACWY-CRM
1-dose
(n=542–554)
MCV4 1-dose
(n=1138–1154)
MenACWY-CRM
1-dose
(n=1136–1161)
86) 77 (73–80) 80 (77–82) 74 (71–76)
62) 63 (59–67) 57 (54–60) 61 (58–64)
44) 58 (54–62) 42 (40–45) 62 (60–65)
49) 57 (53–61) 51 (48–54) 65 (62–67)
pants with a prevaccination antibody titer <4, seroresponse was deﬁned as an hSBA
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Table 5
Geometric mean antibody titer (with 95% conﬁdence interval) by age and vaccine group.
Group 2–5 years 6–10 years Total (2–10 years)
MCV4 1 dose
(n=600–615)
MenACWY-CRM 1
dose (n=593–607)
MenACWY-CRM 2
doses
(n=286–293)
MCV4 1 dose
(n=533–541)
MenACWY-CRM 1
dose (n=542–554)
MCV4 1 dose
(n=1138–1154)
MenACWY-CRM 1
dose
(n=1136–1161)
A
Baseline 2.07 (2.02–2.13) 2.07 (2.02–2.13) 2.1 (2.02–2.18) 2.15 (2.05–2.25) 2.14 (2.04–2.24) 2.11 (2.05–2.16) 2.1 (2.05–2.15)
Postdose 25 (21–29) 26 (22–30) 64 (51–81) 35 (29–41) 35 (29–42) 29 (26–33) 30 (27–34)
C
Baseline 2.75 (2.57–2.94) 2.93 (2.74–3.13) 2.92 (2.65–3.23) 3.82 (3.44–4.25) 3.77 (3.39–4.19) 3.06 (2.89–3.24) 3.14 (2.96–3.32)
Postdose 13 (11–15) 18 (15–20) 144 (118–177) 27 (21–33) 36 (29–45) 17 (15–20) 23 (21–27)
Y
Baseline 2.97 (2.73–3.24) 3.01 (2.77–3.28) 2.75 (2.44–3.09) 4.71 (4.14–5.38) 5.17 (4.52–5.9) 3.36 (3.12–3.62) 3.5 (3.26–3.77)
14 (12
7.97 (6
35 (30
v
o
1
h
s
c
r
s
t
o
t
[
e
a
a
F
(
(Postdose 10 (8.68–12) 24 (20–28) 102 (82–126)
W-135
Baseline 3.95 (3.5–4.46) 4.37 (3.87–4.93) 4.07 (3.42–4.84)
Postdose 21 (19–25) 43 (38–50) 132 (111–157)
accine using immunological surrogates of protection [27]. Based
n the landmark studies of Goldschneider and colleagues in the
960s [26], bactericidal activity at a serum dilution of 1:4 using
uman complement was correlated with protection against inva-
ive meningococcal disease. More recently, Trotter and colleagues
onﬁrmed the inverse correlation of serum bactericidal titer (using
abbit serum and a threshold of 1:8) and incidence of invasive
erogroup C meninogococcal disease in the United Kingdom prior
o universal immunization [28]. However, given the variability
bservedwith biological assays,many regulatory authorities prefer
he use of a 1:8 threshold as a surrogatemeasurement of protection
29]. In contrast to seroprotection where one posits that the pres-
nce of a certain level of antibody will correlate with protection
gainst invasive disease, comparative vaccine studies beneﬁt from
more nuanced analysis. Seroresponse is a measure of an indi-
ig. 2. Proportion of participants achieving hSBA titer ≥8 postvaccination in children 2–5 y
panel A), 6–10 years of age receiving one dose of MenACWY-CRM or MCV4 (panel B), a
panel C). White bars represent MCV4, black bars represent MenACWY-CRM, and striped b–17) 34 (28–41) 12 (11–14) 29 (25–32)
.71–9.46) 8.83 (7.42–10) 4.73 (4.28–5.23) 5.2 (4.7–5.74)
–42) 61 (52–72) 26 (23–29) 49 (44–54)
vidual’s immune response to a meningococcal antigen that may
provide a more complete comparative picture of vaccine response,
including those populations with elevated baseline antibody titers.
In this study, seroresponsewas deﬁned as the development of sero-
protective antibody levels in individuals previously seronegative
to the speciﬁc capsular antigen or a four fold or greater increase
in antibody in individuals already seropositive to that antigen.
Although these measures of immune response and correlates of
protection are based on empiric data and are widely accepted, one
must use caution in interpreting them on an individual level. Cases
of invasive disease have occurred in individuals with antibody lev-
els in excess of the “protective level” and protection provided by
the vaccine under conditions of programmatic use (ﬁeld effective-
ness) have exceeded what would have been predicted using these
thresholds [26,30,31].
ears of age after receiving one or two doses ofMenACWY-CRMor one dose ofMCV4
nd children 2–10 years of age following a single dose of MCV4 or MenACWY-CRM
ars two doses of MenACWY-CRM. Error bars represent the 95% conﬁdence interval.
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The importance of achieving titers beyond the accepted sero-
rotection level has not been clearly deﬁned. The geometric mean
ntibody titer reﬂects at a population level the magnitude of the
accine response and may be predictive of the duration of protec-
ion in diseases where protection is dependent on the presence
f pre-existing antibody. In addition to the statistically superior
eroresponse rates against groups Y and W-135 after MenACWY-
RM, signiﬁcantly higher geometric mean antibody titers were
chieved against groups C, Y, and W-135. Superior seroresponses
gainst groups A, W-135, and Y for MenACWY-CRM when com-
aredwithMCV4have also been observed in another study of these
accines in adolescents [32]. Longer-term follow-up of participants
or immunogenicity testing is planned but whether higher hSBA
MTsatonemonthpostvaccinationwould lead toa longerduration
f protection can only be determined through disease surveillance
fter widespread use of such vaccines.
The results of this study demonstrated that a single-dose reg-
men of the MenACWY-CRM vaccine compared favorably to the
icensed MCV4 vaccine in children 2–10 years of age. Although
imilar (and for some groups superior) to the licensed MCV4,
mmune responses (as measured by seroresponse, seroprotection
r geometric mean antibody titer) to MenACWY-CRM appeared
o increase with age. Although seroresponse and seroprotection
ates in the 2–5-year-olds and 6–10-year-olds were similar, geo-
etric mean antibody titers tended to be higher in the older age
roup. Dramatic increases in rates of seroresponse, seroprotection
nd geometric mean antibody titers were achieved with a second
ose of MenACWY-CRM two months later without any increase
n reported adverse events. These data demonstrate that, as with
nfants and toddlers [21–23], MenACWY-CRM can be safely and
ffectively given in a two-dose schedule should higher rates of
eroresponse or seroprotection be desirable or if higher antibody
evels are demonstrated to increase the duration of protection.
athematical modeling, cost–beneﬁt analyses, and longer-term
ollow-up of vaccine recipients might inform these decisions.
Given the variable epidemiology and geographic distribution of
ifferent groups ofmeningococcal disease [3–6], one can anticipate
hat meningococcal immunization policy will vary regionally in
oth the ageof immunization and theproduct used (meningococcal
conjugate vaccine or quadrivalent meningococcal conjugate vac-
ine). In theUnitedKingdom,where groupCdisease predominated,
niversal monovalent meningococcal C conjugate vaccine pro-
rams were implemented and dramatically reduced the incidence
f invasive disease [13,17]. In the United States, where invasive
isease caused by group Y has emerged over the past decade, uni-
ersal preadolescent immunization programs were implemented
ith the quadrivalent meningococcal conjugate vaccine [2,18–20].
n other countries, such as Canada, universal infant or toddler
mmunization programs were implemented in all provinces with
eningococcal C conjugate vaccine, with some provinces choos-
ng to provide broader meningococcal protection by immunizing
ll preadolescents with the quadrivalent meningococcal conjugate
accine [33]. Finally, due to the unique epidemiology of meningo-
occal disease where, in contrast to Haemophilus inﬂuenzae type
and pneumococcal disease, a second peak of incidence occurs
ater, the need for and timing of a booster vaccination is a topic of
ctive debate [34]. Given the constantly changing epidemiology of
nvasive meningococcal disease, the availability of a quadrivalent
eningococcal vaccine that is immunogenic and well-tolerated in
ll ages will provide more programmatic ﬂexibility by providing
roader coverage to all age groups with a single product.In summary, this study demonstrated that MenACWY-CRM
Menveo®, Novartis Vaccines and Diagnostics), which is currently
icensed in theUnited States, Canada, Australia and Europe for indi-
iduals 11–55 years of age, is immunogenic and well-tolerated
n children 2–10 years of age and compares favorably to MCV428 (2010) 7865–7872 7871
(Menactra®, Sanoﬁ Pasteur) that was previously licensed for this
age group. With previous studies demonstrating the safety and
immunogenicityofMenACWY-CRMin infants and toddlers, a single
product may soon be available to provide broad protection against
groups A, C, Y and W-135 across the age spectrum from infancy to
55 years of age.
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